Reslizumab (Cinqair) for severe eosinophilic asthma.
D018927:Anti-Asthmatic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology / Q000503:physiopathology; D004334:Drug Administration Schedule; D004802:Eosinophilia / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D015848:Interleukin-5 / Q000037:antagonists & inhibitors / Q000276:immunology; D010641:Phenotype; D012720:Severity of Illness Index; D016896:Treatment Outcome
D018927:Anti-Asthmatic Agents; D061067:Antibodies, Monoclonal, Humanized; C508599:IL5 protein, human; D015848:Interleukin-5; C515492:reslizumab